Tag: -mul
Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory Multiple Myeloma
Progression-free survival was not reached after a median 13 months of follow-up
Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard...
Most common SPM subtypes were hematologic malignancies followed by solid tumors, nonmelanoma skin cancers
FDA Approves Darzalex Faspro for Treating Multiple Myeloma
The quadruplet regimen was approved for stem cell transplant-eligible patients
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
Phase 3 trial shows 51 percent reduction in the risk for disease progression or death in triple-class exposed patients
Model Predicts Need for Bone Marrow Sampling in Monoclonal Gammopathy of Undetermined Significance
Model predicts smoldering multiple myeloma or worse among patients with monoclonal gammopathy of undetermined significance
Risk Factors ID’d for Monoclonal Gammopathy of Undetermined Significance
Obesity, heavy smoking, short sleep linked to increased odds of MS-MGUS in individuals at increased risk for multiple myeloma
Robust Score Can ID Infection Risk in Newly Diagnosed Multiple Myeloma
Low platelet count, ISS III, higher WHO performance status, age older than 60 years are risk factors for severe infection/death
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
Addition of daratumumab to VRd results in improved progression-free survival for transplantation-eligible patients
Racial, Ethnic Differences ID’d for Idecabtagene Vicleucel in Multiple Myeloma
Non-Hispanic Black patients more likely to develop cytokine release syndrome; best overall response rate was lower in Hispanics
